Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 27;23(11):122.
doi: 10.1007/s11912-021-01123-w.

Approach to Oligometastatic Cancer in the Elderly Patient

Ian W Winter  1 , Timothy D Smile  1 , Gregory M M Videtic  2
Affiliations
Review

Approach to Oligometastatic Cancer in the Elderly Patient

Ian W Winter et al. Curr Oncol Rep. .

Abstract

Purpose of review: Patients with advanced cancer who have "oligometastatic" disease (OMD) have a limited burden of metastatic sites such that they may benefit from definitive therapies with limited toxicities. The incidence of cancers diagnosed in the elderly is increasing and treatment choices for them are often made because of their vulnerability to side effects. The present review discusses treatment of the elderly with OMD considering cancer outcomes and treatment toxicity.

Recent findings: Stereotactic body radiation therapy (SBRT) is emerging as a standard in the management of OMD because of its excellent local control and minimal toxicity. Phase II trials suggest that SBRT added to palliative therapy may improve overall survival and may delay the initiation of systemic therapy in OMD patients. Elderly patients are well represented in OMD studies SBRT will contribute significantly to the management of OMD in the elderly patient population by optimizing cancer control and limiting side effects.

Keywords: Geriatrics; Oligometastatic cancer; Quality of life; Radiation therapy; Stereotactic body radiotherapy; Toxicity.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/jco.1995.13.1.8 . - DOI - PubMed
    1. Palma DA, Videtic GM. Oligometastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;93(2):223–6. https://doi.org/10.1016/j.ijrobp.2015.07.2277 . - DOI - PubMed
    1. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003 . - DOI - PubMed
    1. • Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://doi.org/10.1016/s1470-2045(19)30718-1 . This review presents a classification scheme for OMD, with subgroups further defined by distribution of disease at presentation, time to development of metastases, and interplay between progression and systemic therapy. - DOI - PubMed
    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–65. https://doi.org/10.1200/jco.2008.20.8983 . - DOI - PubMed

LinkOut - more resources